SYT Antibody (D-3): sc-390615

SYT Antibody (D-3) is a mouse monoclonal IgG2b kappa light chain antibody that detects SYT protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). anti-SYT antibody (D-3) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. SYT protein, known as synovial translocation protein, plays a crucial role as a transcriptional coactivator, containing a conserved amino terminal SNH domain and a carboxy terminal QPGY domain that functions as a transcriptional activating sequence. SYT protein is particularly significant in synovial sarcomas, where the t(x;18) translocation leads to the fusion of SYT with SSX proteins, resulting in the production of potent transcriptional activators. The presence of SYT-SSX chimeras is a hallmark of most synovial sarcomas, which account for up to 10% of soft tissue sarcomas and can be classified into biphasic or monophasic subtypes based on the specific fusion partner involved. Genetic analysis reveals that biphasic synovial sarcomas typically harbor SYT-SSX1 fusions, while monophasic forms are associated with SYT-SSX2 fusions, providing valuable insights for diagnosis and potential therapeutic targeting.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SYT Antibody (D-3) References:

1. SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex.  |  Soulez, M., et al. 1999. Oncogene. 18: 2739-46. PMID: 10348348
2. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome.  |  Nilsson, G., et al. 1999. Cancer Res. 59: 3180-4. PMID: 10397263
3. SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones.  |  Kato, H., et al. 2002. J Biol Chem. 277: 5498-505. PMID: 11734557
4. Real-time polymerase chain reaction as an aid for the detection of SYT-SSX1 and SYT-SSX2 transcripts in fresh and archival pediatric synovial sarcoma specimens: report of 25 cases from St. Jude Children's Research Hospital.  |  Hill, DA., et al. 2003. Pediatr Dev Pathol. 6: 24-34. PMID: 12469233
5. The proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins.  |  Perani, M., et al. 2005. J Biol Chem. 280: 42863-76. PMID: 16227627
6. Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2.  |  Garcia, CB., et al. 2012. BMC Genomics. 13: 189. PMID: 22594313
7. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma.  |  Crew, AJ., et al. 1995. EMBO J. 14: 2333-40. PMID: 7539744
8. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.  |  Clark, J., et al. 1994. Nat Genet. 7: 502-8. PMID: 7951320
9. Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins.  |  dos Santos, NR., et al. 1997. Hum Mol Genet. 6: 1549-58. PMID: 9285793
10. SSX: a multigene family with several members transcribed in normal testis and human cancer.  |  Gure, AO., et al. 1997. Int J Cancer. 72: 965-71. PMID: 9378559
11. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.  |  Kawai, A., et al. 1998. N Engl J Med. 338: 153-60. PMID: 9428816
12. Expression of SSX genes in human tumors.  |  Türeci, O., et al. 1998. Int J Cancer. 77: 19-23. PMID: 9639388

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-SYT Antibody (D-3) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-SYT Antibody (D-3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

SYT Antibody (D-3) Specifications

Alternate Product Name: SS18

Product Clone Name: D-3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 351-380

Epitope Target: SYT

Epitope Species: human

Product Reactivity/Detection: SYT

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for SYT Antibody (D-3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin, X: TransCruz Reagent